Back to discover
Drug

Follicle Stimulating Hormone

Approved · EMA
ClassFollicle stimulating hormone receptor agonistEmerging researchLate-stage developmentRising momentum
Also known as FOLLITROPIN, FSH, Humegon, Menopur+4 more

FOLLITROPIN, FSH, Humegon, Menopur, Pergonal, Pituitary follicle stimulating hormone, Pluset, follitropin (FSH).

11
Research papers
2
Active clinical trials
FSHR
Primary target
1
Regulatory events
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this drug.

Use of Pulsatile Intravenous FSH to Mitigate Reprometabolic Syndrome

Clinical trial2025-11-01Primary completion · ClinicalTrials.gov

Hormone Regulation in Testicular Development and Function.

Research2024-05-26International journal of molecular sciences

Approval: Rekovelle (EMA)

Regulatory2016-12-12EMA

Profile

Identifiers & mechanism

Canonical identifiers, marketed brand names and mechanism, resolved across RxNorm, ChEMBL and ATC.

Canonical name
Follicle Stimulating Hormone
Aliases & brands
FOLLITROPINFSHHumegonMenopurPergonalPituitary follicle stimulating hormonePlusetfollitropin (FSH)
RxNorm CUI
227518
ChEMBL ID
CHEMBL4297955
ATC codes
G03GA10
UNII
076WHW89TW
Primary mechanism
Follicle stimulating hormone receptor agonist
Regulatory jurisdictions
ema

Pharmacology & targets

1 target

Known molecular targets and mechanisms supported by curated pharmacology databases.

AGONISTFollicle stimulating hormone receptor agonist

Regulatory timeline

1 event

The complete regulatory record, grouped by authority — approvals, safety advisories and label changes. Each authority shows its most recent events; expand one to read its full history.

Earliest approval
2016-12-12
Latest approval
2016-12-12
Authorities
EMA
Total events
1
emaEuropean Medicines Agency· 1 event
2016-12-12Approval
Approval: Rekovelle (EMA)
Indication: Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) orShow full indication

Controlled ovarian stimulation for the development of multiple follicles in women undergoing assisted reproductive technologies (ART) such as an in vitro fertilisation (IVF) or intracytoplasmic sperm injection (ICSI) cycle.

Evidence ↗

Contains information from the European Medicines Agency (European Medicines Agency), © EMA, reused under CC BY 4.0.

Clinical trials

16 trials

The current development programme across all trial phases — status mix, phase distribution and the late-stage studies shaping the evidence base.

Development programme
CLINICALTRIALS.GOV · LIVE REGISTRY
16
registered trials across all phases
LATEST COMPLETION 2020
2
Active studies
2
Recruiting
12
Late-stage (III+)
7
Completed
7
Discontinued
PHASE DISTRIBUTIONn = 16
Early Phase 11Phase 11Phase 1 / 21Phase 21Phase 37Phase 43Phase N / A2

Late-stage studies

Phase III+ trials still open or recently active — where late-stage evidence is being generated.

Recent completions

Trials that read out recently, adding to the completed evidence base.

Research activity

11 papers

Key research shaping understanding of this drug, combining the latest publications with the most influential evidence.

Publications over time
20232025
Most influential
Recent papers
Major research themes8
Polycystic Ovary Syndrome4Follicle Stimulating Hormone3Body Mass Index1C-Reactive Protein1Cholecystokinin1Estradiol1Glutamine1Granulosa Cells1
Journals, researchers & institutions
Top journals
  • International journal of molecular sciences2
  • eLife1
  • Frontiers in endocrinology1
  • Gynecological endocrinology : the official journal of the International Society of Gynecological Endocrinology1
  • Journal of affective disorders1
  • Nature communications1
Leading researchers
  • Wang Y3
  • Li Z2
  • Liu Y2
  • Aiznkot T1
  • Bai H1
  • Baranowska M1
  • Bernard DJ1
  • Boehm U1
Leading institutions
free-text, unnormalised
  • Icahn School of Medicine at Mount Sinai2
  • School of Medicine2
  • Cedars-Sinai Medical Center1
  • Centre for Immunobiology1
  • Chinese Academy of Medical Sciences1
  • Clinical Department of Gynecology and Obstetrics1

Related diseases

1 conditions

Regulator-approved indications and conditions co-mentioned with this drug across the research literature. Number shows shared papers.

Active research areas

Related drugs

8 matches

Drugs sharing diseases, protein targets and literature with this one. Ranked by graph evidence (shared targets + diseases weighted above co-mentions).

Studied across 7 of the same disease areas as Follicle Stimulating Hormone in the shared literature.

7 shared diseases6 shared papers

Studied across 6 of the same disease areas as Follicle Stimulating Hormone in the shared literature.

6 shared diseases5 shared papers

Studied across 5 of the same disease areas as Follicle Stimulating Hormone in the shared literature.

5 shared diseases2 shared papers

Studied across 5 of the same disease areas as Follicle Stimulating Hormone in the shared literature.

5 shared diseases1 shared paper

Studied across 5 of the same disease areas as Follicle Stimulating Hormone in the shared literature.

5 shared diseases1 shared paper

Studied across 3 of the same disease areas as Follicle Stimulating Hormone in the shared literature.

3 shared diseases1 shared paper

Studied across 3 of the same disease areas as Follicle Stimulating Hormone in the shared literature.

3 shared diseases1 shared paper

Studied across 2 of the same disease areas as Follicle Stimulating Hormone in the shared literature.

2 shared diseases1 shared paper
References & data sources
  • RxNorm (U.S. National Library of Medicine) — drug identity
  • ChEMBL (EMBL-EBI) & UniProt — pharmacology and targets
  • Europe PMC — research literature
  • ClinicalTrials.gov — clinical trials
  • Regulatory event sources are credited in the Regulatory Timeline above.